NeuroBo Pharmaceuticals has signed a joint research agreement, together with Dong-A ST and ImmunoForge to develop a long-acting, once-monthly, formulation of DA-1726, a novel, dual oxyntomodulin analog agonist that functions as a glucagon-like peptide-1 receptor and glucagon receptor, utilizing ImmunoForge’s long-lasting half-life extension Elastin-Like Polypeptide platform technology. Financial terms of the agreement were not disclosed.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRBO:
- NeuroBo Pharmaceuticals Strikes Licensing Deal for NB-01
- NeuroBo Pharmaceuticals announces license agreement with MThera Pharma
- NeuroBo Pharmaceuticals files to sell 17.18M shares of common stock for holders
- NeuroBo Pharmaceuticals Releases Corporate Presentation Update
- NeuroBo Pharmaceuticals doses first patient in MAD Part 2 of DA-1726 trial